ArticleCancers2021
Identification of Potential Prognostic and Predictive Immunological Biomarkers in Patients with Stage I and Stage III Non-Small Cell Lung Cancer (NSCLC): A Prospective Exploratory Study.
Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 45 citations in OpenAlex.
- Induction Serplulimab and Chemotherapy Followed by Chemoradiotherapy for Bulky Unresectable Stage III NSCLC: A Phase II Study (SUCCEED-01).Cancer immunology research · 2026Trial
- Trial
- PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis.Journal for immunotherapy of cancer · 2023Trial
- Normoxic HIFα-mediated metabolic rewiring in cancer as a novel therapeutic target of tumor heterogeneity.Cancer & metabolism · 2026Article
- Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade.Molecular cancer · 2026Review
- CD244 overexpression indicates NK cell dysfunction and tumor progression in diffuse large B-cell lymphoma.Frontiers in immunology · 2026Article
- CXCL10 promotes non-small cell lung cancer (NSCLC) progression by modulating the phosphate to urate ratio (PUR).Discover oncology · 2025Article
- Liquid biopsy using plasma proteomics in predicting efficacy and tolerance of PD-1/PD-L1 blockades in NSCLC: a prospective exploratory study.Molecular biomedicine · 2025Article
- A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.Cancers · 2025Review
- The prognostic and predictive value of peripheral immune-related proteins in patients with lung cancer treated with radiotherapy.Frontiers in oncology · 2025Review
- Induction immunochemotherapy followed by definitive chemoradiotherapy and consolidation immunotherapy for unresectable stage III non-small cell lung cancer: a multi-institutional retrospective cohort study.Frontiers in immunology · 2025Article
- Article
- Prognostic value of circulating proteins at diagnosis among patients with lung cancer: a comprehensive analysis by smoking status.Translational lung cancer research · 2024Article
- Distinct roles of CD244 expression in cancer diagnosis and prognosis: A pan-cancer analysis.Heliyon · 2024Article
- Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2024Article
- Targeting serine/glycine metabolism improves radiotherapy response in non-small cell lung cancer.British journal of cancer · 2024Article
- Trial watch: anticancer vaccination with dendritic cells.Oncoimmunology · 2024Review
- Identifying potential therapeutic targets in lung adenocarcinoma: a multi-omics approach integrating bulk and single-cell RNA sequencing with Mendelian randomization.Frontiers in pharmacology · 2024Article
- Signaling lymphocytic activation molecule family receptors as potential immune therapeutic targets in solid tumors.Frontiers in immunology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy (RT) and chemotherapy can induce immune responses, but not much is known regarding treatment-induced immune changes in patients. This exploratory study aimed to identify potential prognostic and predictive immune-related proteins associated with progression-free survival (PFS) in patients with non-small cell lung cancer (NSCLC). In this prospective study, patients with stage I NSCLC treated with stereotactic body radiation therapy (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.